



PCT

RAW SEQUENCE LISTING

DATE: 10/13/2004

PATENT APPLICATION: US/10/510,101

TIME: 15:01:54

Input Set : A:\sequence listing ascii.txt

Output Set: N:\CRF4\10132004\J510101.raw

4 <110> APPLICANT: Epimmune Inc.
 5 Ishioka, Glenn
 6 Fikes, John
 7 Tangri, Shabnam
 8 Sette, Alessandro
 10 <120> TITLE OF INVENTION: Heteroclitic Analogs and Related Methods
 12 <130> FILE REFERENCE: 2060.009PC05
 C--> 14 <140> CURRENT APPLICATION NUMBER: US/10/510,101
 C--> 14 <141> CURRENT FILING DATE: 2004-10-05
 14 <150> PRIOR APPLICATION NUMBER: US 60/413,471
 15 <151> PRIOR FILING DATE: 2002-09-26
 17 <150> PRIOR APPLICATION NUMBER: US 10/116,118
 18 <151> PRIOR FILING DATE: 2002-04-05
 20 <160> NUMBER OF SEQ ID NOS: 196
 22 <170> SOFTWARE: PatentIn version 3.2
 24 <210> SEQ ID NO: 1
 25 <211> LENGTH: 9
 26 <212> TYPE: PRT
 27 <213> ORGANISM: Artificial Sequence
 29 <220> FEATURE:
 30 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens carcinoembryonic
 31 antigen
 33 <400> SEQUENCE: 1
 35 Ile Met Ile Gly Val Leu Val Gly Val
 36 1 5
 39 <210> SEQ ID NO: 2
 40 <211> LENGTH: 9
 41 <212> TYPE: PRT
 42 <213> ORGANISM: Artificial Sequence
 44 <220> FEATURE:
 45 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens carcinoembryonic
 46 antigen
 48 <400> SEQUENCE: 2
 50 Ile Met Met Gly Val Leu Val Gly Val
 51 1 5
 54 <210> SEQ ID NO: 3
 55 <211> LENGTH: 9
 56 <212> TYPE: PRT
 57 <213> ORGANISM: Artificial Sequence
 59 <220> FEATURE:
 60 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens carcinoembryonic
 61 antigen
 63 <400> SEQUENCE: 3

CPS-6
ENTERED

RAW SEQUENCE LISTING

DATE: 10/13/2004

PATENT APPLICATION: US/10/510,101

TIME: 15:01:54

Input Set : A:\sequence listing ascii.txt

Output Set: N:\CRF4\10132004\J510101.raw

```

65 Ile Met Ile Gly His Leu Val Gly Val
66 1          5
69 <210> SEQ ID NO: 4
70 <211> LENGTH: 9
71 <212> TYPE: PRT
72 <213> ORGANISM: Artificial Sequence
74 <220> FEATURE:
75 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens melanoma antigens
77 <400> SEQUENCE: 4
79 Lys Val Ala Glu Leu Val His Phe Leu
80 1          5
83 <210> SEQ ID NO: 5
84 <211> LENGTH: 9
85 <212> TYPE: PRT
86 <213> ORGANISM: Artificial Sequence
88 <220> FEATURE:
89 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens melanoma antigens
91 <400> SEQUENCE: 5
93 Lys Val Ala Glu Ile Val His Phe Leu
94 1          5
97 <210> SEQ ID NO: 6
98 <211> LENGTH: 9
99 <212> TYPE: PRT
100 <213> ORGANISM: Artificial Sequence
102 <220> FEATURE:
103 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens melanoma
antigens
105 <400> SEQUENCE: 6
107 Lys Val Ala Glu Leu Val Trp Phe Leu
108 1          5
111 <210> SEQ ID NO: 7
112 <211> LENGTH: 10
113 <212> TYPE: PRT
114 <213> ORGANISM: Artificial Sequence
116 <220> FEATURE:
117 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens melanoma
antigens
119 <400> SEQUENCE: 7
121 Tyr Leu Gln Leu Val Phe Gly Ile Glu Val
122 1          5          10
125 <210> SEQ ID NO: 8
126 <211> LENGTH: 10
127 <212> TYPE: PRT
128 <213> ORGANISM: Artificial Sequence
130 <220> FEATURE:
131 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens melanoma
antigens
133 <400> SEQUENCE: 8
135 Tyr Leu Gln Leu Ile Phe Gly Ile Glu Val
136 1          5          10
139 <210> SEQ ID NO: 9
140 <211> LENGTH: 10

```

RAW SEQUENCE LISTING

DATE: 10/13/2004

PATENT APPLICATION: US/10/510,101

TIME: 15:01:54

Input Set : A:\sequence listing ascii.txt

Output Set: N:\CRF4\10132004\J510101.raw

141 <212> TYPE: PRT
 142 <213> ORGANISM: Artificial Sequence
 144 <220> FEATURE:
 145 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens melanoma
 antigens
 147 <400> SEQUENCE: 9
 149 Tyr Leu Gln Leu Phe Phe Gly Ile Glu Val
 150 1 5 10
 153 <210> SEQ ID NO: 10
 154 <211> LENGTH: 9
 155 <212> TYPE: PRT
 156 <213> ORGANISM: Artificial Sequence
 158 <220> FEATURE:
 159 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens carcinoembryonic
 160 antigen
 162 <400> SEQUENCE: 10
 164 His Leu Phe Gly Tyr Ser Trp Tyr Lys
 165 1 5
 168 <210> SEQ ID NO: 11
 169 <211> LENGTH: 9
 170 <212> TYPE: PRT
 171 <213> ORGANISM: Artificial Sequence
 173 <220> FEATURE:
 174 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens carcinoembryonic
 175 antigen
 177 <400> SEQUENCE: 11
 179 His Leu Phe Pro Tyr Ser Trp Tyr Lys
 180 1 5
 183 <210> SEQ ID NO: 12
 184 <211> LENGTH: 9
 185 <212> TYPE: PRT
 186 <213> ORGANISM: Artificial Sequence
 188 <220> FEATURE:
 189 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens carcinoembryonic
 190 antigen
 192 <400> SEQUENCE: 12
 194 His Leu Phe Ile Tyr Ser Trp Tyr Lys
 195 1 5
 198 <210> SEQ ID NO: 13
 199 <211> LENGTH: 9
 200 <212> TYPE: PRT
 201 <213> ORGANISM: Artificial Sequence
 203 <220> FEATURE:
 204 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens carcinoembryonic
 205 antigen
 207 <400> SEQUENCE: 13
 209 His Leu Phe Gly Tyr Ser Leu Tyr Lys
 210 1 5
 213 <210> SEQ ID NO: 14
 214 <211> LENGTH: 9

RAW SEQUENCE LISTING

DATE: 10/13/2004

PATENT APPLICATION: US/10/510,101

TIME: 15:01:54

Input Set : A:\sequence listing ascii.txt

Output Set: N:\CRF4\10132004\J510101.raw

```

215 <212> TYPE: PRT
216 <213> ORGANISM: Artificial Sequence
218 <220> FEATURE:
219 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens carcinoembronic
220     antigen
222 <400> SEQUENCE: 14
224 His Leu Phe Gly Tyr Ser Met Tyr Lys
225 1           5
228 <210> SEQ ID NO: 15
229 <211> LENGTH: 9
230 <212> TYPE: PRT
231 <213> ORGANISM: Artificial Sequence
233 <220> FEATURE:
234 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens carcinoembronic
235     antigen
237 <400> SEQUENCE: 15
239 His Leu Phe Gly Tyr Ser Ile Tyr Lys
240 1           5
243 <210> SEQ ID NO: 16
244 <211> LENGTH: 9
245 <212> TYPE: PRT
246 <213> ORGANISM: Artificial Sequence
248 <220> FEATURE:
249 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens carcinoembronic
250     antigen
252 <400> SEQUENCE: 16
254 His Leu Phe Gly Tyr Ser Asp Tyr Lys
255 1           5
258 <210> SEQ ID NO: 17
259 <211> LENGTH: 9
260 <212> TYPE: PRT
261 <213> ORGANISM: Artificial Sequence
263 <220> FEATURE:
264 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens carcinoembronic
265     antigen
267 <400> SEQUENCE: 17
269 His Leu Phe Gly Tyr Ser Gly Tyr Lys
270 1           5
273 <210> SEQ ID NO: 18
274 <211> LENGTH: 9
275 <212> TYPE: PRT
276 <213> ORGANISM: Artificial Sequence
278 <220> FEATURE:
279 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens carcinoembronic
280     antigen
282 <400> SEQUENCE: 18
284 His Leu Phe Gly Tyr Ser Cys Tyr Lys
285 1           5
288 <210> SEQ ID NO: 19

```

RAW SEQUENCE LISTING

DATE: 10/13/2004

PATENT APPLICATION: US/10/510,101

TIME: 15:01:54

Input Set : A:\sequence listing ascii.txt

Output Set: N:\CRF4\10132004\J510101.raw

```

289 <211> LENGTH: 9
290 <212> TYPE: PRT
291 <213> ORGANISM: Artificial Sequence
293 <220> FEATURE:
294 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens carcinoembryonic
295     antigen
297 <400> SEQUENCE: 19
299 His Leu Phe Gly Tyr Ser Asn Tyr Lys
300 1             5
303 <210> SEQ ID NO: 20
304 <211> LENGTH: 9
305 <212> TYPE: PRT
306 <213> ORGANISM: Artificial Sequence
308 <220> FEATURE:
309 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens melanoma
antigens
311 <400> SEQUENCE: 20
313 Glu Tyr Leu Gln Leu Val Phe Gly Ile
314 1             5
317 <210> SEQ ID NO: 21
318 <211> LENGTH: 9
319 <212> TYPE: PRT
320 <213> ORGANISM: Artificial Sequence
322 <220> FEATURE:
323 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens melanoma
antigens
325 <400> SEQUENCE: 21
327 Glu Tyr Ile Gln Leu Val Phe Gly Ile
328 1             5
331 <210> SEQ ID NO: 22
332 <211> LENGTH: 9
333 <212> TYPE: PRT
334 <213> ORGANISM: Artificial Sequence
336 <220> FEATURE:
337 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens melanoma
antigens
339 <400> SEQUENCE: 22
341 Glu Tyr Leu Glu Leu Val Phe Gly Ile
342 1             5
345 <210> SEQ ID NO: 23
346 <211> LENGTH: 9
347 <212> TYPE: PRT
348 <213> ORGANISM: Artificial Sequence
350 <220> FEATURE:
351 <223> OTHER INFORMATION: Synthetic peptide derived from Homo sapiens melanoma
antigens
353 <400> SEQUENCE: 23
355 Glu Tyr Leu Leu Leu Val Phe Gly Ile
356 1             5
359 <210> SEQ ID NO: 24
360 <211> LENGTH: 9
361 <212> TYPE: PRT
362 <213> ORGANISM: Artificial Sequence

```

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/510,101

DATE: 10/13/2004
TIME: 15:01:55

Input Set : A:\sequence listing ascii.txt
Output Set: N:\CRF4\10132004\J510101.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:29; Xaa Pos. 3
Seq#:30; Xaa Pos. 3
Seq#:31; Xaa Pos. 3
Seq#:72; Xaa Pos. 734,1028,2501

VERIFICATION SUMMARY

DATE: 10/13/2004

PATENT APPLICATION: US/10/510,101

TIME: 15:01:55

Input Set : A:\sequence listing ascii.txt

Output Set: N:\CRF4\10132004\J510101.raw

L:14 M:270 C: Current Application Number differs, Replaced Current Application No
L:14 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:458 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29 after pos.:0
L:488 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:30 after pos.:0
L:518 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31 after pos.:0
L:1733 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:72 after pos.:720
M:341 Repeated in SeqNo=72